The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland. There is no treatment involved in this study, this is only an observational review of ongoing/initiating treatment data relating to Vedolizumab induction and maintenance treatment for IBD \[including Ulcerative Colitis (UC) and Crohn's Disease (CD)\].
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants Persisting on Treatment With Vedolizumab IV Compared to Participants With Treatment Change up to 24 Months
Timeframe: Baseline up to 24 months
Time to any Treatment Change
Timeframe: Baseline up to 24 months
Number of Participants Who Discontinued Vedolizumab Treatment
Timeframe: Baseline up to 24 months
Number of Participants With Reason for Treatment Change
Timeframe: Baseline up to 24 months
Number of Participants With Change in Vedolizumab Dosing Frequency
Timeframe: Baseline up to 24 months
Number of Participants Who Changed to Another Treatment
Timeframe: Baseline up to 24 months